Sionna Therapeutics Inc(SION) - 2025 Q4 - Annual Report

Drug Development and Pipeline - The company is developing novel medicines targeting the cystic fibrosis transmembrane conductance regulator (CFTR) protein, aiming to restore normal CFTR function for approximately 90% of cystic fibrosis patients who carry the F508del mutation[29]. - SION-719, a potent NBD1 stabilizer, is currently in a Phase 2a trial, with topline data expected in mid-2026, following positive Phase 1 results announced in June 2025[37][38]. - The company’s pipeline includes SION-451, also a potent NBD1 stabilizer, which is being evaluated in dual combinations with other modulators, with topline data anticipated in mid-2026[37][38]. - The ongoing Phase 2a PreciSION CF trial is evaluating SION-719 in combination with Trikafta, with topline data expected in mid-2026[83]. - The company has advanced both SION-451 and SION-719 to the next phase of development, targeting NBD1 stabilization for CF treatment[80]. - The company expects topline data from the Phase 1 dual combination trial of SION-451 in mid-2026[94]. - SION-109 is currently being evaluated in combination with SION-451 in a Phase 1 dual combination trial, following successful Phase 1 trials for safety and tolerability[137]. Treatment Efficacy and Patient Outcomes - The current standard of care, Trikafta, does not stabilize NBD1, and at least two-thirds of patients on Trikafta do not achieve normal CFTR function, defined as sweat chloride levels below 30 mmol/L[55]. - Approximately 69% of patients treated with Alyftrek did not achieve normal CFTR function, indicating a significant unmet need for more effective treatment options[56]. - Two-thirds of CF patients on Trikafta still have sweat chloride levels above normal, indicating ongoing CFTR dysfunction[58]. - A two-year interim study showed that while pulmonary exacerbations improved, they were not normalized, and mental health issues increased among patients on Trikafta[59]. - Alyftrek demonstrated non-inferiority to Trikafta, with sweat chloride improvements of approximately 3 to 8 mmol/L, but 69% of patients did not achieve normal CFTR function[60]. - The median predicted survival age for individuals with cystic fibrosis born in the U.S. between 2020 and 2024 is just 65 years, highlighting the ongoing need for improved therapies[45]. Safety and Tolerability - SION-719 was generally well tolerated, with no serious adverse events reported, and 60% of participants experienced any treatment-emergent adverse events (TEAEs) across all doses[86]. - The most common TEAEs included headache (23%), diarrhea (10%), and nausea (8%), with no TEAEs leading to treatment discontinuation[87]. - SION-451 was also well tolerated, with 50% of participants experiencing any TEAEs, and no serious adverse events reported[98]. - The most frequent TEAEs for SION-451 included headache (18%) and influenza (5%), with no TEAEs leading to treatment discontinuation[99]. - SION-109 was generally well tolerated across all dose levels in the Phase 1 trial, with 38% of participants experiencing any treatment-emergent adverse events (TEAEs) and no serious adverse events reported[140][141]. - The most frequent TEAEs included headache (13%), abdominal pain (5%), and increased alanine aminotransferase (5%)[142]. - The majority of adverse events reported in clinical trials for SION-2222 were mild to moderate, indicating a favorable safety profile[129]. Mechanism of Action and Preclinical Findings - Preclinical studies indicated that SION-719 and SION-451 increased NBD1 thermal stability by approximately 16°C compared to ETI[106]. - Binding affinity for SION-719 to F508del-NBD1 was approximately 4.3 nM, while SION-451 had a binding affinity of approximately 2.4 nM[108]. - Both SION-719 and SION-451 showed potential to restore F508del-CFTR folding and maturation to levels similar to wild-type CFTR[109]. - SION-719 and SION-451 improved the half-life of F508del-CFTR to 12.6 hours and 14.2 hours respectively, compared to 1.7 hours for F508del-CFTR alone[116]. - Treatment with SION-719 as a single agent demonstrated a greater effect on F508del maturation than ETI, achieving wild-type levels of corrected F508del-CFTR protein[112]. - In the CFHBE model, SION-719 and SION-451 improved F508del-CFTR activity to levels near those observed with the triple combination ETI[120]. - SION-451 in combination with SION-2222 or SION-109 showed significant improvements in CFTR function, with half-lives reaching 16.4 hours[116]. Intellectual Property and Licensing - The company aims to expand and protect its intellectual property estate to maximize the value of its pipeline[48]. - The company co-owns a patent family with Sanofi covering SION-719 and SION-451, with a statutory expiration date of September 2043[159]. - The patent family covering SION-109 has a statutory expiration date of November 2040, indicating a strong intellectual property position[160]. - The company entered into a license agreement with Sanofi, paying an upfront fee of $1.5 million and a reimbursement of $0.3 million for R&D expenses, with potential milestone payments of up to $40.0 million[167]. - The company is required to pay royalties to Sanofi in the low single-digit percentage range based on net sales of licensed products, with the royalty term terminating upon the expiration of the last-to-expire patent claim or regulatory exclusivity[167]. - The company entered into a license agreement with AbbVie, paying an upfront fee of $5.0 million and issuing 1,414,445 shares of common stock, with potential milestone payments of up to $360.0 million[180]. - The company is required to pay royalties to AbbVie in the low to mid single-digit percentage range based on net sales of licensed products, with the royalty term terminating similarly to the Sanofi agreement[180]. - The AbbVie License Agreement includes a right of first negotiation for AbbVie regarding any commercial license transaction prior to Phase 3 clinical trials[181]. - The company has assumed all global development and commercialization responsibilities for three clinical-stage CFTR modulator therapies under the AbbVie License Agreement[178]. Regulatory Compliance and Market Considerations - Regulatory compliance is critical, with extensive requirements imposed by the FDA and other authorities, necessitating significant time and financial resources for drug development and approval[186]. - The company must submit an IND to the FDA before beginning the first clinical trial in the U.S., which includes preclinical test results and manufacturing information[190]. - Clinical trials are conducted in three phases: Phase 1 focuses on safety and dosage, Phase 2 evaluates efficacy and safety in a limited patient population, and Phase 3 generates data for FDA approval[199]. - The FDA has a goal of reviewing standard NDAs within ten months and priority NDAs within six months from the filing date[208]. - The FDA may require a Risk Evaluation and Mitigation Strategy (REMS) as a condition of approval to ensure the drug's benefits outweigh its risks[207]. - A Complete Response Letter from the FDA indicates that the application will not be approved in its current form and outlines deficiencies that must be addressed[211]. - The company must submit progress reports detailing clinical trial results at least annually to the FDA[200]. - The FDA conducts inspections of manufacturing facilities to ensure compliance with cGMP requirements before approving an NDA[205]. - The company must disclose results of clinical trials after completion, with penalties for failure to register or report results timely[197]. - Pediatric data requirements must be met for certain NDAs, and the FDA may grant deferrals or waivers under specific circumstances[209]. - The FDA may impose conditions on approved products that can significantly affect market potential and profitability, including post-approval studies and risk management mechanisms[212]. - Orphan Drug Designation allows for exclusivity for seven years if the product is the first FDA-approved treatment for a rare disease, with specific conditions for maintaining exclusivity[215]. - The FDA's Fast Track designation facilitates expedited review for drugs addressing serious conditions, allowing rolling submissions of NDA sections[218]. - Breakthrough Therapy designation provides intensive guidance from the FDA and similar benefits to Fast Track, aimed at drugs showing substantial improvement over existing therapies[220]. - Priority Review designation shortens the FDA's review timeline from ten months to six months for drugs that significantly improve safety and effectiveness[221]. - Accelerated Approval allows drugs to be approved based on surrogate endpoints, contingent on post-approval confirmatory studies to verify clinical benefits[222]. - The Hatch-Waxman Amendments establish a five-year non-patent exclusivity period for new chemical entities, delaying ANDA submissions until this period expires[226]. - Three years of market exclusivity is granted for non-NCE NDAs if new clinical investigations are essential for approval, protecting new indications or dosages[227]. Competitive Landscape - The company faces substantial competition from established players like Vertex, which has multiple approved CFTR modulators, including Trikafta[152]. - The CF patient populations are well-characterized, with treatment typically occurring at centralized CF care centers, suggesting a focused approach for commercialization[150].